Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.

Meenakshi Anurag,Henry Rodriguez,Jonathan T Lei,Erik J Bergstrom,Bora Lim,Viktoriya Korchina,Gloria V Echeverria,Shunqiang Li,Anh Minh Tran Huynh,Mothaffar F Rimawi,Lacey E Dobrolecki,Ian S Hagemann,Julie R Nangia,Karsten Krug,Donna M Muzny,Maryam Nemati Shafaee,Richard A Gibbs,Michael A Gillette,Chen Huang,Matthew J Ellis,Tara Hiltke,Foluso O Ademuyiwa,Bing Zhang,Yongchao Dou,Xuxu Gou,Beom-Jun Kim,Ana I Robles,George Miles,Harshavardhan Doddapaneni,Eric J Jaehnig,C Kent Osborne,Shankha Satpathy,Zhiao Shi,Tanmayi D Vashist,Jeremy Hoog,Steven A Carr,Michael T Lewis,Bo Wen,D R Mani

doi:10.1158/2159-8290.cd-22-0200

Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer.

Meenakshi Anurag, Henry Rodriguez + Show 37 more

Open Access

https://doi.org/10.1158/2159-8290.cd-22-0200

Copy DOI

Journal: Cancer Discovery	Publication Date: Aug 24, 2022
Citations: 33	License type: CC BY-NC-ND 4.0

Affiliation: Baylor College of Medicine, National Cancer Institute, Cancer Clinic, Massachusetts Institute of Technology, Broad Institute, Baylor Genetics, Washington University in St. Louis, Massachusetts General Hospital

#Response In Triple-negative Breast Cancer #Lack Of Pathologic Response + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Proteogenomic analysis of triple-negative breast tumors revealed a complex landscape of chemotherapy response associations, including a 19q13.31-33 somatic deletion encoding genes serving lagging-strand DNA synthesis (LIG1, POLD1, and XRCC1), that correlate with lack of pathologic response, carboplatin-selective resistance, and, in pan-cancer studies, poor prognosis and CIN. This article is highlighted in the In This Issue feature, p. 2483.

Full Text